Publications by authors named "Ross Camidge"

Claim this Profile
B
Bivalent CD47 Immunotoxin for Targeted Therapy of Lung Cancer.
Jihong Ma, Dinoop Ravindran Menon, Zhaohui Wang, Danielle Mintzlaff, Hugh Rock, D Ross Camidge

bioRxiv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Lyudmila Bazhenova, J G Hodgson, D Ross Camidge, Corey J Langer, Rudolf M Huber

Clin Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics of Short-Term Survivors With or -Altered Metastatic NSCLC.
Kai-Lin Liu, Alex Watts, Connor B Grady, Geoffrey Liu, Devalben Patel, D Ross Camidge

JTO Clin Res Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable response with mutation-guided inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report.
Sumra S Chaudhry, D Ross Camidge, Michael R Clay, Breelyn A Wilky

Rare Tumors· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer.
Jair Bar, Mona H Cai, Yookyung Christy Choi, Shobhit Baijal, Weilong Zhao, D Ross Camidge

Acta Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors.
Alexander S Watson, Alyse W Staley, Benjamin Yoder, Sean J Iwamoto, Vida Alami, D Ross Camidge

JTO Clin Res Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Amin H Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat, Hassan Abushukair, D Ross Camidge

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
Charu Aggarwal, Alex Martinez-Marti, Margarita Majem, Fabrice Barlesi, Enric Carcereny, D Ross Camidge

JAMA Netw Open· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center.
Ahmed Alsafar, Sama L Kareem, Bradley R Corr, Christopher H Lieu, Breelyn Wilky, D Ross Camidge

Front Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments.
William J Phillips, Alexander S Watson, D Ross Camidge

J Thorac Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis.
Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins, D Ross Camidge

Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.
Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, Ludovic Doucet, Jianying Zhou, D Ross Camidge

Cell Rep Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.
Nicolas Girard, Qingqing Xu, D Ross Camidge, Shobhit Baijal, Sophia Ng

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer.
Byoung Chul Cho, Melissa Johnson, Jair Bar, Eric Schaefer, Kiyotaka Yoh, D Ross Camidge

Lung Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.
David E Gerber, Claire R Wynters, Tanushree Prasad, Ronny K Schnel, Song Zhang, D Ross Camidge

Clin Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials.
D Ross Camidge, Shunichi Sugawara, Masashi Kondo, Hye Ryun Kim, Myung-Ju Ahn

Lung Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun, D Ross Camidge

Nature· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, Leora Horn, D Ross Camidge

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with NSCLC.
Jürgen Wolf, Sarah Goring, Adam Lee, Byoung Chul Cho, Alexander Drilon, D Ross Camidge

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
Tejas Patil, Dexiang Gao, Alexander Watson, Mandy Sakamoto, Yunan Nie, D Ross Camidge

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Margaret Stalker, Connor B Grady, Alex Watts, Wei-Ting Hwang, Krishna Chandrasekhara, D Ross Camidge

JTO Clin Res Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso, D Ross Camidge

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC.
David Chun Cheong Tsui, Jessica K Lee, Candice Francheska B Tambaoan, Jason Hughes, Bernard Fendler, D Ross Camidge

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy.
William J Phillips, D Ross Camidge, Paul Wheatley-Price

J Thorac Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Connor B Grady, Wei-Ting Hwang, Joshua E Reuss, Wade Iams, Amanda Cass, D Ross Camidge

Pharmacoepidemiol Drug Saf· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis